Search Result

Results for "

neurotransmitters dopamine

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Dopamine Receptor (10) Dopamine Transporter (2) 5-HT Receptor (1) Apoptosis (2) Autophagy (2) Biochemical Assay Reagents (1) Caspase (2) COX (2) Endogenous Metabolite (8) Interleukin Related (2) Isotope-Labeled Compounds (5) Mitophagy (2) Monoamine Transporter (1) p38 MAPK (2) PGE synthase (2) Serotonin Transporter (2)
By Research Areas:	Cancer (4) Metabolic Disease (1) Neurological Disease (13)

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: Dopamine Receptor Dopamine Transporter Dopamine β-hydroxylase

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-N0304

L-DOPA 10+ Cited Publications Levodopa; 3,4-Dihydroxyphenylalanine	Dopamine Receptor Endogenous Metabolite	Neurological Disease Cancer
L-DOPA (Levodopa) is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA can cross the blood-brain barrier and is converted into dopamine in the brain. L-DOPA has anti-allodynic effects and the potential for Parkinson's disease .

HY-14472

Tesofensine NS-2330	Dopamine Transporter Serotonin Transporter	Metabolic Disease
Tesofensine (NS-2330) is a triple monoamine reuptake inhibitor inducing a potent inhibition of the re-uptake process in the synaptic cleft of the neurotransmitters dopamine (DA; IC₅₀=6.5 nM), norepinephrine (NE;IC₅₀=1.7 nM), and serotonin (5-HT;IC₅₀=11 nM), and with potentials as an anti-obesity agent . Tesofensine is a CNS acting anti-obesity agent .

HY-N0304A

L-DOPA sodium Levodopa sodium; 3,4-Dihydroxyphenylalanine sodium	Dopamine Receptor Endogenous Metabolite	Neurological Disease
L-DOPA (Levodopa) sodium is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA sodium can cross the blood-brain barrier and is converted into dopamine in the brain. L-DOPA sodium has anti-allodynic effects, and can be used for Parkinson's disease research .

HY-110019

Indatraline hydrochloride Lu 19-005	Serotonin Transporter Dopamine Transporter	Neurological Disease
Indatraline hydrochloride (Lu 19-005) is a non-selective monoamine transporter inhibitor that blocks the reuptake of neurotransmitters (dopamine, serotonin, and norepinephrine). Indatraline hydrochloride can be used for the research of antidepressive. Indatraline hydrochloride induces autophagy while simultaneously inhibiting cell proliferation. Indatraline hydrochloride may also serve to direct the development of new agents for autophagy-related diseases such as atherosclerosis or restenosis .

HY-103465

FFN511	Monoamine Transporter	Others
FFN511 is a potent fluorescent false neurotransmitters (FFNs) that targets neuronal vesicular monoamine transporter 2 (VMA T2). FFN511 inhibits serotonin binding to VMA T2-containing membranes with an IC₅₀ of 1 µM. FFN511 directly images the dynamics of release during exocytosis, can be used to label dopamine terminals in live cortical-striatalacute slices .

HY-101540

NMI 8739

Dopamine Receptor Neurological Disease

NMI 8739 is a dopamine D₂ autoreceptor agonist, which is an amine conjugate of the DHA carrier and the neurotransmitter dopamine.

NMI 8739	Dopamine Receptor	Neurological Disease
NMI 8739 is a dopamine D₂ autoreceptor agonist, which is an amine conjugate of the DHA carrier and the neurotransmitter dopamine.

HY-Y0123S1

DL-Tyrosine-d7	Isotope-Labeled Compounds
DL-Tyrosine-d₇ is the deuterium labeled DL-Tyrosine. DL-Tyrosine is an aromatic nonessential amino acid synthesized from the essential amino acid phenylalanine. DL-Tyrosine is a precursor for several important neurotransmitters (epinephrine, norepinephrine, dopamine)[1][2].

HY-Y0123S2

DL-Tyrosine-d2	Isotope-Labeled Compounds
DL-Tyrosine-d₂ is the deuterium labeled DL-Tyrosine. DL-Tyrosine is an aromatic nonessential amino acid synthesized from the essential amino acid phenylalanine. DL-Tyrosine is a precursor for several important neurotransmitters (epinephrine, norepinephrine, dopamine)[1][2].

HY-Y0123S3

DL-Tyrosine-d3	Isotope-Labeled Compounds
DL-Tyrosine-d₃ is the deuterium labeled DL-Tyrosine. DL-Tyrosine is an aromatic nonessential amino acid synthesized from the essential amino acid phenylalanine. DL-Tyrosine is a precursor for several important neurotransmitters (epinephrine, norepinephrine, dopamine)[1][2].

HY-Y0123

DL-Tyrosine	Others	Neurological Disease
DL-Tyrosine is an aromatic nonessential amino acid synthesized from the essential amino acid phenylalanine. DL-Tyrosine is a precursor for several important neurotransmitters (epinephrine, norepinephrine, dopamine) .

HY-Y0123S

DL-Tyrosine-13C9,15N	Isotope-Labeled Compounds	Neurological Disease
DL-Tyrosine- ¹³C₉, ¹⁵N is the ¹³C- and ¹⁵N-labeled DL-Tyrosine. DL-Tyrosine is an aromatic nonessential amino acid synthesized from the essential amino acid phenylalanine. DL-Tyrosine is a precursor for several important neurotransmitters (epinephrine, norepinephrine, dopamine)[1].

HY-132392S

L-DOPA-2,5,6-d3	Dopamine Receptor Endogenous Metabolite	Neurological Disease
L-DOPA-2,5,6-d₃ is the deuterium labeled L-DOPA. L-DOPA (Levodopa) is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA can cross the blood-brain barrier and is converted into dopamine in the brain[1][2][3].

HY-N0304S

L-DOPA-d6 Levodopa-d₆; 3,4-Dihydroxyphenylalanine-d₆	Dopamine Receptor Endogenous Metabolite	Neurological Disease
L-DOPA-d₆ is the deuterium labeled L-DOPA. L-DOPA (Levodopa) is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA can cross the blood-brain barrier and is converted into dopamine in the brain. L-DOPA has anti-allodynic effects and the potential for Parkinson's disease[1][2][3].

HY-N0304S1

L-DOPA-13C6 Levodopa-¹³C₆; 3,4-Dihydroxyphenylalanine-¹³C₆	Dopamine Receptor Endogenous Metabolite
L-DOPA- ¹³C₆ is the ¹³C-labled L-DOPA . L-DOPA (Levodopa) is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA can cross the blood-brain barrier and is converted into dopamine in the brain. L-DOPA has anti-allodynic effects and the potential for Parkinson's disease .

HY-N0304S2

L-DOPA-13C 1 Publications Verification	Dopamine Receptor Endogenous Metabolite
L-DOPA- ¹³C is the ¹³C labeled L-DOPA[1]. L-DOPA (Levodopa) is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA can cross the blood-brain barrier and is converted into dopamine in the brain. L-DOPA has anti-allodynic effects and the potential for Parkinson's disease[2][3][4].

HY-N0304R

L-DOPA (Standard) Levodopa (Standard); 3,4-Dihydroxyphenylalanine (Standard)	Dopamine Receptor Endogenous Metabolite	Neurological Disease Cancer
L-DOPA (Standard) is the analytical standard of L-DOPA. This product is intended for research and analytical applications. L-DOPA (Levodopa) is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA can cross the blood-brain barrier and is converted into dopamine in the brain. L-DOPA has anti-allodynic effects and the potential for Parkinson's disease .

HY-W250174

Lithium 3,5-diiodosalicylate 3,5-Diiodosalicylic acid lithium salt	Biochemical Assay Reagents	Others
Lithium 3,5-diiodosalicylate is a compound used in the study of bipolar disorder and other psychiatric disorders. It contains lithium and a salicylate. Lithium 3,5-diiodosalicylate works by affecting the levels of certain neurotransmitters in the brain, including dopamine and serotonin.

HY-W011727A

Pyridoxal 5'-phosphate monohydrate 1 Publications Verification Pyridoxal phosphate monohydrate	Endogenous Metabolite	Neurological Disease
Pyridoxal 5'-phosphate hydrate, the active form of vitamin B6, is an essential cofactor for multiple enzymes, including aromatic l-amino acid decarboxylase that catalyzes the final stage in the production of the neurotransmitters dopamine and serotonin. Pyridoxal 5'-phosphate hydrate is the most important coenzyme variant in the process of vitamin B6 intracellular phosphorylation and is interconvertible with other variants, including pyridoxine 5′‐phosphate (PNP) and pyridoxamine 5′‐phosphate (PMP) .

HY-B1081

Oxidopamine hydrochloride Maximum Cited Publications 14 Publications Verification 6-Hydroxydopamine hydrochloride; 6-OHDA hydrochloride	Dopamine Receptor Autophagy Mitophagy COX PGE synthase Interleukin Related p38 MAPK Apoptosis Caspase	Neurological Disease Cancer
Oxidopamine (6-OHDA) hydrochloride is an antagonist of the **neurotransmitter dopamine. Oxidopamine hydrochloride is a widely used neurotoxin and selectively destroys dopaminergic neurons. Oxidopamine hydrochloride promotes COX-2 activation, leading to PGE₂ synthesis and pro-inflammatory cytokine IL-1β** secretion. Oxidopamine hydrochloride can be used for the research of Parkinson’s disease (PD), attention-deficit hyperactivity disorder (ADHD), and Lesch-Nyhan syndrome .

HY-B1081A

Oxidopamine hydrobromide Maximum Cited Publications 14 Publications Verification 6-Hydroxydopamine hydrobromide; 6-OHDA hydrobromide	Dopamine Receptor Autophagy Mitophagy COX PGE synthase Interleukin Related p38 MAPK Apoptosis Caspase	Neurological Disease Cancer
Oxidopamine (6-OHDA) hydrobromide is an antagonist of the **neurotransmitter dopamine. Oxidopamine hydrobromide is a widely used neurotoxin and selectively destroys dopaminergic neurons. Oxidopamine hydrobromide promotes COX-2 activation, leading to PGE₂ synthesis and pro-inflammatory cytokine IL-1β** secretion. Oxidopamine hydrobromide can be used for the research of Parkinson’s disease (PD), attention-deficit hyperactivity disorder (ADHD), and Lesch-Nyhan syndrome .

HY-A0095S1

Flibanserin-d4-1 BIMT-17-d₄-1; BIMT-17BS-d₄-1	Isotope-Labeled Compounds 5-HT Receptor	Neurological Disease
Flibanserin-d₄-1 is deuterium labeled Flibanserin. Flibanserin (BIMT-17) is a full agonist of the serotonin 5-HT1A receptor (Ki=1 nM) and an antagonist of 5-HT2A (49 nM). Flibanserin binds to dopamine D4 receptors (4-24 nM), and has negligible affinity for a variety of other neurotransmitter receptors and ion channels. Flibanserin is efficacious in treating hypoactive sexual desire disorder (HSDD)[1][2].

Cat. No.	Product Name

HY-L062

Neurotransmitter Receptor Compound Library	1785 compounds
Neurotransmitter (NT) receptors, also known as neuroreceptors, are a broadly diverse group of membrane proteins that bind neurotransmitters for neuronal signaling. There are two major types of neurotransmitter receptors: ionotropic and metabotropic. Ionotropic receptors are ligand-gated ion channels, meaning that the receptor protein includes both a neurotransmitter binding site and an ion channel. The binding of a neurotransmitter molecule (the ligand) to the binding site induces a conformational change in the receptor structure, which opens, or gates, the ion channel. The term “metabotropic receptors” is typically used to refer to transmembrane G-protein-coupled receptors. Metabotropic receptors trigger second messenger-mediated effects within cells after neurotransmitter binding. In some neurological diseases, the neurotransmitter receptor itself appears to be the target of the disease process. Many neuroactive drugs act by modifying neurotransmitter receptors. A better understanding of neurotransmitter receptor changes in disease may lead to improvements in therapy. MCE designs a unique collection of 1785 compounds targeting a variety of neurotransmitter receptors. MCE Neurotransmitter Receptor Compound Library is a useful tool for neurological diseases drug discovery.

Neurotransmitter Receptor Compound Library

1785 compounds

Neurotransmitter (NT) receptors, also known as neuroreceptors, are a broadly diverse group of membrane proteins that bind neurotransmitters for neuronal signaling. There are two major types of neurotransmitter receptors: ionotropic and metabotropic. Ionotropic receptors are ligand-gated ion channels, meaning that the receptor protein includes both a neurotransmitter binding site and an ion channel. The binding of a neurotransmitter molecule (the ligand) to the binding site induces a conformational change in the receptor structure, which opens, or gates, the ion channel. The term “metabotropic receptors” is typically used to refer to transmembrane G-protein-coupled receptors. Metabotropic receptors trigger second messenger-mediated effects within cells after neurotransmitter binding.

In some neurological diseases, the neurotransmitter receptor itself appears to be the target of the disease process. Many neuroactive drugs act by modifying neurotransmitter receptors. A better understanding of neurotransmitter receptor changes in disease may lead to improvements in therapy.

MCE designs a unique collection of 1785 compounds targeting a variety of neurotransmitter receptors. MCE Neurotransmitter Receptor Compound Library is a useful tool for neurological diseases drug discovery.

HY-L165

Dopamine Receptor Compound Library	195 compounds
Dopamine receptor (DAR), widely distributed in the brain, plays a key role in regulating motor function, motivation, driving force and cognition. The role of DA is mediated by D1-type (D1, D5) and D2-type receptors (D2S, D2L, D3, D4), which are distributed in presynaptic, postsynaptic and extrasynaptic, projection neurons and interneurons. Each receptor has a different function. D1 and D5 receptors couple with G stimulation sites and activate Adenylyl cyclase. The activation of Adenylyl cyclase leads to the production of the second messenger cAMP, which leads to the production of protein kinase A (PKA), which leads to further transcription in the nucleus. D2 to D4 receptors are coupled to G inhibitory sites to inhibit adenylyl cyclase and activate potassium Ion channel. These receptors utilize phosphorylation cascades or direct membrane interactions to affect the functions of voltage-gated and neurotransmitter-gated channels, cytoplasmic enzymes, and transcription factors. Dopamine receptor plays an important role in daily life. MCE designs a unique collection of 195 small molecules related to dopamine receptor. It is a good tool for screening drugs from nervous system disease.

Dopamine Receptor Compound Library

195 compounds

Dopamine receptor (DAR), widely distributed in the brain, plays a key role in regulating motor function, motivation, driving force and cognition. The role of DA is mediated by D1-type (D1, D5) and D2-type receptors (D2S, D2L, D3, D4), which are distributed in presynaptic, postsynaptic and extrasynaptic, projection neurons and interneurons. Each receptor has a different function. D1 and D5 receptors couple with G stimulation sites and activate Adenylyl cyclase. The activation of Adenylyl cyclase leads to the production of the second messenger cAMP, which leads to the production of protein kinase A (PKA), which leads to further transcription in the nucleus. D2 to D4 receptors are coupled to G inhibitory sites to inhibit adenylyl cyclase and activate potassium Ion channel. These receptors utilize phosphorylation cascades or direct membrane interactions to affect the functions of voltage-gated and neurotransmitter-gated channels, cytoplasmic enzymes, and transcription factors. Dopamine receptor plays an important role in daily life.

MCE designs a unique collection of 195 small molecules related to dopamine receptor. It is a good tool for screening drugs from nervous system disease.

Lithium 3,5-diiodosalicylate 3,5-Diiodosalicylic acid lithium salt	Biochemical Assay Reagents
Lithium 3,5-diiodosalicylate is a compound used in the study of bipolar disorder and other psychiatric disorders. It contains lithium and a salicylate. Lithium 3,5-diiodosalicylate works by affecting the levels of certain neurotransmitters in the brain, including dopamine and serotonin.

Cat. No.	Product Name	Category	Target	Chemical Structure